Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China Team is First to Inject CRISPR-edited Genes into Human

publication date: Nov 16, 2016
A team led by Lu You, an oncologist at Chengdu's Sichuan University, became the first to inject CRISPR–Cas9 edited genes into a patient. The patient has metastatic non-small cell lung cancer. The team extracted immune cells from the unnamed person, used CRISPR–Cas9 editing tools to delete the PD-1 immune system checkpoint, expanded the edited cells and injected them back into the patient. The ten-patient trial will administer two, three and four rounds of the treatment, with safety being the primary endpoint, though everyone will be equally interested in any signs of efficacy. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital